• Elevance Health recently reported another earnings beat, raised its outlook, and authorized billions of dollars in additional share buybacks, underscoring tight control over utilization and pricing.
• Despite its scale, capital returns, and reputation as a defensive growth name, the company still appears underappreciated by many US investors.
• With Elevance Health boosting its outlook and accelerating buybacks, we'll explore how this earnings momentum affects the existing investment narrative.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Elevance Health Investment Narrative Recap

To own Elevance Health, you need to believe its scale, data, and disciplined pricing can offset rising medical costs in ACA and Medicaid plans. The latest earnings beat and outlook raise support that view in the near term, but the biggest risk remains persistent medical cost pressure and lagging Medicaid rate updates. The quarter reinforces management’s cost control, yet it does not remove uncertainty around reimbursement and policy changes that could still weigh on margins.

The standout recent development tied to this story is Elevance Health’s expanded share repurchase activity, with billions of US$ already deployed. This capital return sits alongside regular dividends, including the latest increase to US$1.72 per share for the first quarter of 2026. Together, these moves matter for the catalyst of earnings per share growth, since a shrinking share count can amplify any improvement in core profitability if cost trends and pricing hold steady.

Yet against this constructive picture, investors should also be aware of how policy shifts around ACA subsidies and Medicaid could suddenly reshape Elevance’s risk pools and...

Elevance Health’s narrative projects $230.4 billion revenue and $7.4 billion earnings by 2028. This requires 6.8% yearly revenue growth and about a $2.0 billion earnings increase from $5.4 billion today.

Uncover how Elevance Health's forecasts yield a $387.85 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were factoring in only about US$224.2 billion of revenue and roughly US$5.3 billion of earnings by 2028, so their more cautious view on ACA and Medicaid cost pressures might shift meaningfully in light of Elevance’s recent earnings beat and higher outlook.

Explore 10 other fair value estimates on Elevance Health - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Elevance Health research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Elevance Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Elevance Health's overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.